Medivation is venturing into the immune-oncology arena, licensing CureTech's late-stage anti PD-1 monoclonal antibody pidilizumab (CT-011), in an effort to diversify its portfolio, currently dominated by the prostate cancer treatment Xtandi (enzalutamide; licensed to Astellas).
Under the agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

